Cargando…

Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma

BACKGROUND: The use of opioids in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is associated with shorter survival and not dependent on the expression of the mu-opioid receptor (MOR). The role of opioid use and MOR expression in stage I-III PDAC has not been investigated. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao, Qu, Mengdi, Gorur, Aysegul, Sun, Zhirong, Cata, Juan P., Chen, Wankun, Miao, Changhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249918/
https://www.ncbi.nlm.nih.gov/pubmed/34222012
http://dx.doi.org/10.3389/fonc.2021.686877
_version_ 1783717001531752448
author Zhang, Hao
Qu, Mengdi
Gorur, Aysegul
Sun, Zhirong
Cata, Juan P.
Chen, Wankun
Miao, Changhong
author_facet Zhang, Hao
Qu, Mengdi
Gorur, Aysegul
Sun, Zhirong
Cata, Juan P.
Chen, Wankun
Miao, Changhong
author_sort Zhang, Hao
collection PubMed
description BACKGROUND: The use of opioids in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is associated with shorter survival and not dependent on the expression of the mu-opioid receptor (MOR). The role of opioid use and MOR expression in stage I-III PDAC has not been investigated. METHODS: We conducted retrospective study in patients with stage I-III PDAC. MOR expression and OPRM1 gene expression in tumour tissue and non-tumour tissue was measured. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Secondary endpoints included perineural invasion, intraoperative sufentanil consumption, and length of stay. We performed a subgroup group analysis to evaluate the interaction between levels of MOR expression, amount of opioids use (high versus low) and its association with survival. RESULTS: A total of 236 patients were enrolled in this study.There were no significantly difference in OS rates in patients with high versus low levels of MOR (1-year OS: 65.2% versus 70.6%, P=0.064; 3-year: 31.4% versus 35.8%, P=0.071; 5-year: 19.4% versus. 16.2%, P=0.153, respectively) in the tumours. The DFS rates between the groups were no significantly difference. Of note, a high expression of MOR combined with high opioid consumption was associated with poor prognosis in stage I-III PDAC patients. Tumor expressing high levels of MOR show higher rates of perineural invasion. CONCLUSION: MOR is not an independent predictor of poor survival in stage I-III PDAC but associated with perineural invasion. Patients requiring high amounts of opioids intraoperatively show worse outcome if they are expressing high levels of MOR.
format Online
Article
Text
id pubmed-8249918
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82499182021-07-03 Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma Zhang, Hao Qu, Mengdi Gorur, Aysegul Sun, Zhirong Cata, Juan P. Chen, Wankun Miao, Changhong Front Oncol Oncology BACKGROUND: The use of opioids in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is associated with shorter survival and not dependent on the expression of the mu-opioid receptor (MOR). The role of opioid use and MOR expression in stage I-III PDAC has not been investigated. METHODS: We conducted retrospective study in patients with stage I-III PDAC. MOR expression and OPRM1 gene expression in tumour tissue and non-tumour tissue was measured. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Secondary endpoints included perineural invasion, intraoperative sufentanil consumption, and length of stay. We performed a subgroup group analysis to evaluate the interaction between levels of MOR expression, amount of opioids use (high versus low) and its association with survival. RESULTS: A total of 236 patients were enrolled in this study.There were no significantly difference in OS rates in patients with high versus low levels of MOR (1-year OS: 65.2% versus 70.6%, P=0.064; 3-year: 31.4% versus 35.8%, P=0.071; 5-year: 19.4% versus. 16.2%, P=0.153, respectively) in the tumours. The DFS rates between the groups were no significantly difference. Of note, a high expression of MOR combined with high opioid consumption was associated with poor prognosis in stage I-III PDAC patients. Tumor expressing high levels of MOR show higher rates of perineural invasion. CONCLUSION: MOR is not an independent predictor of poor survival in stage I-III PDAC but associated with perineural invasion. Patients requiring high amounts of opioids intraoperatively show worse outcome if they are expressing high levels of MOR. Frontiers Media S.A. 2021-06-18 /pmc/articles/PMC8249918/ /pubmed/34222012 http://dx.doi.org/10.3389/fonc.2021.686877 Text en Copyright © 2021 Zhang, Qu, Gorur, Sun, Cata, Chen and Miao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Hao
Qu, Mengdi
Gorur, Aysegul
Sun, Zhirong
Cata, Juan P.
Chen, Wankun
Miao, Changhong
Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma
title Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma
title_full Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma
title_fullStr Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma
title_short Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma
title_sort association of mu-opioid receptor(mor) expression and opioids requirement with survival in patients with stage i-iii pancreatic ductal adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249918/
https://www.ncbi.nlm.nih.gov/pubmed/34222012
http://dx.doi.org/10.3389/fonc.2021.686877
work_keys_str_mv AT zhanghao associationofmuopioidreceptormorexpressionandopioidsrequirementwithsurvivalinpatientswithstageiiiipancreaticductaladenocarcinoma
AT qumengdi associationofmuopioidreceptormorexpressionandopioidsrequirementwithsurvivalinpatientswithstageiiiipancreaticductaladenocarcinoma
AT goruraysegul associationofmuopioidreceptormorexpressionandopioidsrequirementwithsurvivalinpatientswithstageiiiipancreaticductaladenocarcinoma
AT sunzhirong associationofmuopioidreceptormorexpressionandopioidsrequirementwithsurvivalinpatientswithstageiiiipancreaticductaladenocarcinoma
AT catajuanp associationofmuopioidreceptormorexpressionandopioidsrequirementwithsurvivalinpatientswithstageiiiipancreaticductaladenocarcinoma
AT chenwankun associationofmuopioidreceptormorexpressionandopioidsrequirementwithsurvivalinpatientswithstageiiiipancreaticductaladenocarcinoma
AT miaochanghong associationofmuopioidreceptormorexpressionandopioidsrequirementwithsurvivalinpatientswithstageiiiipancreaticductaladenocarcinoma